60 Degrees Pharmaceuticals Announces Minimum Enrollment Achieved in Hospitalized Babesiosis Study; Interim Data Readout Planned by October 6, 2026

Data ReadoutPositive

AI Analysis

Summary

60 Degrees Pharmaceuticals announced minimum enrollment achievement in its hospitalized babesiosis trial with interim data readout expected by October 6, 2026.

Clinical Trial Data

Outcome Details

interim analysis data readout planned

Importance:6/10

Sentiment:

0.50

clinical trialinterim datababesiosisenrollment milestone

Read the original article

Published by GlobeNewswire Clinical Studies on July 29, 2026 8:03 PM

Read Original